Toll-like receptor 4deficient mice are resistant to chronic hypoxia-induced pulmonary hypertension

Experimental Lung Research

Volumn 36, Issue 2, 2010, Pages 111-119

  Young, Karen C ^a   Hussein, Sameh M A ^a,b   Dadiz, Rita ^a,c   Demello, Daphne ^d   Devia, Carlos ^a   Hehre, Dorothy ^a   Suguihara, Cleide ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d PHOENIX CHILDREN'S HOSPITAL   (United States)

Author keywords

Chronic hypoxia; Pulmonary hypertension; Toll like receptor 4; Vascular remodeling

Indexed keywords

GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TOLL LIKE RECEPTOR 4; HIF1A PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; INFLAMMATION; LONG TERM EXPOSURE; LUNG BLOOD VESSEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; ANIMAL; ANOXIA; BLOOD PRESSURE; C3H MOUSE; GENETICS; LUNG; METABOLISM; PATHOPHYSIOLOGY; VASCULARIZATION;

ANIMALS; ANOXIA; BLOOD PRESSURE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION; LUNG; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C3H; TOLL-LIKE RECEPTOR 4;

EID: 77749304560     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902140903171610     Document Type: Article

References (46)

1. Frantz S, Ertl G, Bauersachs J: Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007;4:444-454.
2. Hashimoto C, Hudson KL, Anderson KV: The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988;52:269-279.
3. Kaczorowski DJ, Mollen KP, Edmonds R, Billiar TR: Early events in the recognition of danger signals after tissue injury. J Leukoc Biol. 2008;83:546-552.
4. Li H, Sun B: Toll-like receptor 4 in atherosclerosis. J Cell Mol Med. 2007;11:88-95.
5. Becker MN, Diamond G, Verghese MW, Randell SH: CD14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem. 2000;275:29731-29736.
6. Faure E, Thomas L, Xu H, Medvedev A, Equils O, Arditi M: Bacterial lipopolysaccharide and IFN-gamma induce Tolllike receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol. 2001;166:2018-2024.
7. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103-3108.
8. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-2088.
9. Poltorak A, Smirnova I, He X, Liu MY, Van Huffel C, McNally O, Birdwell D, Alejos E, Silva M, Du X, Thompson P, Chan EK, Ledesma J, Roe B, Clifton S, Vogel SN, Beutler B: Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis. 1998;24:340-355.
10. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Hacker H, Wagner H: Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem. 2001;276:31332-31339.
11. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd: The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001;276:10229-10233.
12. Smiley ST, King JA, Hancock WW: Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol. 2001;167:2887-2894.
13. Watari M, Watari H, Nachamkin I, Strauss JF: Lipopolysac-charide induces expression of genes encoding pro-inflammatory cytokines and the elastin-degrading enzyme, cathepsin S, in human cervical smooth-muscle cells. J Soc Gynecol Investig. 2000;7:190-198.
14. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
15. Kaisho T, Akira S: Toll-like receptors and their signaling mechanism in innate immunity. Acta Odontol Scand. 2001;59:124-130.
16. O'Neill LA, Dinarello CA: The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today. 2000;21:206-209.
17. Durmowicz AG, Parks WC, Hyde DM, Mecham RP, Stenmark KR: Persistence, re-expression, and induction of pulmonary arterial fibronectin, tropoelastin, and type I procollagen mRNA expression in neonatal hypoxic pulmonary hypertension. Am J Pathol. 1994;145:1411-1420.
18. Laudi S, Steudel W, Jonscher K, Schoning W, Schniedewind B, Kaisers U, Christians U, Trump S: Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension. Proteomics. 2007;7:2469-2478.
19. Madjdpour C, Jewell UR, Kneller S, Ziegler U, Schwendener R, Booy C, Klausli L, Pasch T, Schimmer RC, Beck-Schimmer B: Decreased alveolar oxygen induces lung inflammation. Am J Physiol Lung Cell Mol Physiol. 2003;284:L360-L367.
20. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, Kourembanas S: Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci U S A. 2001;98:8798-8803.
21. Stenmark KR, Davie NJ, Reeves JT, Frid MG: Hypoxia, leukocytes, and the pulmonary circulation. J Appl Physiol. 2005;98:715-721.
22. Korshunov VA, Berk BC: Strain-dependent vascular remodeling: the "Glagov phenomenon" is genetically determined. Circulation. 2004;110:220-226.
23. Δ4. Blood. 2004;103:110-119.
24. Rabinovitch M: Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med. 2001;22:433-449.
25. Bull TM, Coldren CD, Moore M, Sotto-Santiago SM, Pham DV, Nana-Sinkam SP, Voelkel NF, Geraci MW: Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:911-919.
26. Raychaudhuri B, Bonfield TL, Malur A, Hague K, Kavuru MS, Arroliga AC, Thomassen MJ: Circulating monocytes from patients with primary pulmonary hypertension are hyporesponsive. Clin Immunol. 2002;104:191-198.
27. Michelsen KS, Doherty TM, Shah PK, Arditi M: TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol. 2004;173:5901-5907.
28. Michelsen KS, Doherty TM, Shah PK, Arditi M: Role of Tolllike receptors in atherosclerosis. Circ Res. 2004:95:e96-e97.
29. Stoll LL, Denning GM, Li WG, Rice JB, Harrelson AL, Romig SA, Gunnlaugsson ST, Miller FJ Jr, Weintraub NL: Regulation of endotoxin-induced proinflammatory activation in human coronary artery cells: expression of functional membrane-bound CD14 by human coronary artery smooth muscle cells. J Immunol. 2004;173:1336-1343.
30. Vink A, Schoneveld AH, Van Der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB, Quax PH, Lim SK, Borst C, Pasterkamp G, de Kleijn DP: In vivo evidence for a role of tolllike receptor 4 in the development of intimal lesions. Circulation. 2002;106:1985-1990.
31. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pasterkamp G, de Kleijn DP: Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008;102:257-264.
32. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, William Browder I, Kao RL, Li C: Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res. 2005;68:224-234.
33. Oyama J, Blais C, Jr., Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T: Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation. 2004;109:784-789.
34. Ogawa Y, Tasaka S, Yamada W, Saito F, Hasegawa N, Miyasho T, Ishizaka A: Role of Toll-like receptor 4 in hyperoxia-induced lung inflammation in mice. Inflamm Res. 2007;56:334-338.
35. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M: Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004;101:10679-10684.
36. Smith RM, McCarthy J, Sack MN: TNF alpha is required for hypoxia-mediated right ventricular hypertrophy. Mol Cell Biochem. 2001;219:139-143.
37. Fujita M, Shannon JM, Irvin CG, Fagan KA, Cool C, Augustin A, Mason RJ: Overexpression of tumor necrosis factoralpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;280: L39-L49.
38. Ito T, Okada T, Miyashita H, Nomoto T, Nonaka-Sarukawa M, Uchibori R, Maeda Y, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Shimada K, Ozawa K: Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res. 2007;101:734-741.
39. Grenier D, Grignon L: Response of human macrophagelike cells to stimulation by Fusobacterium nucleatum ssp. nucleatum lipopolysaccharide. Oral Microbiol Immunol. 2006;21:190-196.
40. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251-262.
41. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P: Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-189.
42. Russell REK, Thorley A, Culpitt SV, Dodd S, Donnelly LE, Demattos C, Fitzgerald M, Barnes PJ: Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol. 2002;283:L867-L873.
43. Herget J, Novotna J, Bibova J, Povysilova V, Vankova M, Hampl V: Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol. 2003;285:L199-L208.
44. Peyssonnaux C, Cejudo-Martin P, Doedens A, Zinkernagel AS, Johnson RS, Nizet V: Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J Immunol. 2007;178:7516-7519.
45. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9:677-684.
46. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL: Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest. 1999;103:691-696.